Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H9E3
UPID:
COG4_HUMAN
Alternative names:
Component of oligomeric Golgi complex 4
Alternative UPACC:
Q9H9E3; B4DMN8; C9JS23; Q96D40; Q9BRF0; Q9BVZ2; Q9H5Y4; Q9Y3W3
Background:
Conserved oligomeric Golgi complex subunit 4, also known as Component of oligomeric Golgi complex 4, is pivotal for normal Golgi function. It facilitates SNARE-pin assembly and Golgi-to-ER retrograde transport through its interaction with SCFD1. This protein's role underscores the intricate mechanisms ensuring cellular cargo transport and processing.
Therapeutic significance:
The protein is linked to Congenital disorder of glycosylation 2J and Saul-Wilson syndrome, diseases stemming from gene variants affecting this protein. Understanding its function could pave the way for innovative treatments targeting these genetic disorders, highlighting its therapeutic potential.